Allarity Therapeutics (NASDAQ:ALLR) Shares Up 3.3% – Still a Buy?

Allarity Therapeutics, Inc. (NASDAQ:ALLR) traded up 3.3% during trading on Wednesday. The company traded as high as $0.9594 and last traded at $0.95. 69,803 shares traded hands during mid-day trading, a decline of 54% from the average daily volume of 151,492 shares. The stock had previously closed at $0.92.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $10.25.

Allarity Therapeutics Stock Down 2.2%

The stock’s fifty day simple moving average is $1.10 and its 200-day simple moving average is $1.22.

Allarity Therapeutics (NASDAQ:ALLR) last announced its earnings results on Friday, August 14th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.04. On average, equities research analysts expect that Allarity Therapeutics, Inc. will post -0.80 earnings per share for the current fiscal year.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc (NASDAQ: ALLR) is a clinical-stage biotechnology company focused on developing personalized treatments for cancer. The company uses its Drug Response Predictor (DRP) technology to analyze patient and tumor characteristics and identify individuals who may be more likely to respond to specific drug candidates.

Allarity’s development programs have included stenoparib, also known as 2X-121, an orally administered PARP inhibitor being investigated for potential use in oncology.